Anthem Will Reduce Planned Premium Hikes
After facing scrutiny from California regulators, Anthem Blue Cross will ease up 2 planned premium increases for 2018. According to California Healthline, the state’s regulators had challenged Anthem’s estimates for costs, which led to it planning a 40% premium increase for individuals and families. The insurer will shave 3 percentage points off its increase, which still makes its 37.3% increase the second highest hike among Covered California’s 11 insurers.
Second Gene Therapy Gets Endorsed
An FDA advisory committee has endorsed another gene therapy. The committee voted unanimously, 16-0, for a therapy to treat an inherited disorder that causes a progressive form of blindness, reported NPR. The FDA does not have to follow recommendations from advisory committees. If the therapy is approved, the cost is expected to be hundreds of thousands of dollars for each eye, but the manufacturer hasn’t yet said how much it would charge.
California Wildfires Strain Medical Services
The fires in California have forced hospital evacuations, destroyed medical offices, and increased the number of patients that need to be seen at the remaining hospitals and health centers that are open. The Los Angeles Times reported that one health center is only helping people who require urgent care, such as those struggling to breathe amid the poor air quality, people who hurt themselves fleeing, or those who left behind needed medications. In addition, medical personnel are still preparing for changing or worsening conditions in case the fires aren’t contained, the wind changes direction, or there is an earthquake.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
2 Commerce Drive
Cranbury, NJ 08512